BCL2 and breast carcinoma: Furthermore, EGCG can bind with high affinity to many other target proteins in cancer cells, such as 70 kDa zeta-associated protein (Zap-70) [41], 67-kDa laminin receptor [42], phosphoinositide 3 kinase (PI3K) [31], Ras-GTPase activating protein (GAP), SH3 domain-binding protein 1 (G3BP1) [43], insulin-like growth factor 1 receptor (IGF-1R) [44], vimentin [45], Bcl-2 and Bcl-xL [46], GRP78 [47], and Fyn [48], resulting in the inhibition of breast cancer.